Skip to main content
OpenTrials
Completed

NCT Number: NCT03386487

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

A Phase 2B, 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults with DSM-5 Current Cannabis Use Disorder (CUD)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cannabis Use Disorder

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Connecticut Mental Health Center, New Haven, Connecticut, United States

Loading trial locations.

About this study

The efficacy, safety and tolerability of the FAAH Inhibitor PF-0447845 in reducing cannabis use will be studied in a 4-site randomized, double-blind, placebo-controlled, parallel-group, outpatient clinical trial comparing PF-04457845 (4mg) and placebo in DSM-5 CUD individuals. Participants will be randomized in a 1:1 ratio to either PF-04457845 or placebo using random block sizes of 2 and 4, stratified by site and degree of cannabis use. Participants will receive motivational interviewing for 2 weeks before being randomized to receive study medication to make a quit attempt within the first week of treatment. Participants will receive active or placebo PF-04457845 for 8 weeks during which time they will be evaluated weekly in face to face visits. In addition, daily assessment of adherence to study medication and cannabinoid use will be conducted daily by cellphone. Measures of cannabinoid exposure (self-reported and urine toxicology), and problems related to the use of cannabis, will be assessed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 18-60 years, inclusive.
  • Male or Female.
  • Individuals with DSM-V criteria for Cannabis Use Disorder .
  • Positive for urinary THC-COOH at both screening visits.
  • Must express a willingness at screening to set a date within the first week of randomization to attempt to quit using cannabis.

Exclusion criteria

  • Clinically significant unstable medical disorders (as determined by the site investigator).
  • Laboratory tests with clinically significant abnormalities (as determined by the site investigator)
  • Pregnancy by history and or laboratory confirmation (serum HCG).
  • Lactation.
  • Physiological dependence on another substance.

Treatment and study plan

PF 04457845

Drug

Study medication will be administered at 4mg by mouth daily for eight weeks.

Placebo oral tablet

Drug

Placebo comparator will be administered by mouth daily for eight weeks.

Primary outcomes

  1. Time Line Follow Back (TLFB) for Cannabis Use

    Time frame: Change from baseline in self reported cannabis use as measured by the TLFB approach at baseline and then weekly average daily use over 8 weeks.

    Change in the average number of times per day of self-reported cannabis consumption measured by the Timeline Follow Back approach for Cannabis Use in which participants quantify and report their frequency of cannabis use prior to study participation and throughout the study. Differences between groups in the change from baseline use (2 weeks prior to randomization) in the average number of times per day of self-reported consumption of cannabis or a cannabis containing product in the last 4 weeks of treatment captured using the daily TLFB data collected during CAROMA calls.

  2. Urinary Levels of THC-COOH (ng/ml)

    Time frame: baseline, week 1, week 3, week 5, week 7, and week 9 visits

    Assay of the levels of the principal metabolite of THC (THC-COOH) in urine samples at baseline and bi-weekly over 8 weeks.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • Columbia University
  • Johns Hopkins University
  • Medical University of South Carolina
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

A Phase 2B, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)

Acronym: FAAH-I MULTI

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Dec 29, 2017
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.